Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 144-146, 2008.
Artículo
en Chino
| WPRIM
| ID: wpr-348148
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the efficacy of the combination of gemcitabine with capecitabine in the chemotherapy for patients with relapsed or metastatic biliary tract carcinoma.</p><p><b>METHODS</b>Forty-one patients with unresectable relapsed or metastatic carcinoma of the biliary tract were treated from March 2000 to December 2004. The regimen consisted of intravenous administration of gemcitabine plus oral intake of capecitabine every 3 weeks for more than 2 cycles. The parameters including tumor response, clinical benefit rate,survival and safety were observed.</p><p><b>RESULTS</b>Thirty-six patients were valuable and 5 patients were excluded from this series due to various reasons. Eleven patients (30.1%) had a partial response and another 11 patients (30.1%) experieced stable disease with a clinical benefit rates of 61.1%. The median overall survival time and time to progression were 10 months and 6 months, respectively. The one-year survival rate was 40.0%. The adverse events including nausea, diarrhea and hand-foot syndrome, fatigue, neutropenia, thrombocytopenia were frequently observed, which were usually in grade I or II, rarely in grade III and none in grade IV (NCI-CTC).</p><p><b>CONCLUSION</b>Our results show that the regimen of gemcitabine combined with capecitabine is effective and well tolerated in patients with unresectable relapsed or metastatic carcinoma of the biliary tract.</p>
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Patología
/
Neoplasias de los Conductos Biliares
/
Conductos Biliares Intrahepáticos
/
Inducción de Remisión
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Tasa de Supervivencia
/
Estudios de Seguimiento
/
Colangiocarcinoma
/
Usos Terapéuticos
/
Desoxicitidina
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
Límite:
Adulto
/
Anciano
/
Femenino
/
Humanos
/
Masculino
Idioma:
Chino
Revista:
Chinese Journal of Oncology
Año:
2008
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS